Vestal Point Capital, LP — 13F Holdings & Portfolio
CIK 1974915 · latest 13F-HR filed 2026-08-14
Vestal Point Capital, LP manages $4.28B in 13F-reported U.S. long-equity assets across 68 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BMRN (8.06%), NBIX (7.40%), ABVX (7.32%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 33; 36 existing positions rose in reported value and 18 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 50.3%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CARROLL, BENJAMIN, GERMAN Control | CHIEF FINANCIAL OFFICER since Mar 2025 | Less than 5% | Individual |
| MENKOV, ILKO, LATCHEZAROV Control | PARTNER, COO AND CCO since Apr 2023 | 5–10% | Individual |
| VESTAL POINT CAPITAL, LLC Control | GENERAL PARTNER since Apr 2023 | Less than 5% | Domestic Entity |
| WILDER, RYAN, CHRISTOPHER Control | MANAGING PARTNER AND CHIEF INVESTMENT OFFICER since Apr 2023 | 25–50% | Individual |
| MAPLEWOOD 1 HOLDINGS LLC | LIMITED PARTNER since Jan 2026 | 25–50% | Domestic Entity |
| WILDER, RYAN, CHRISTOPHER Control Indirect owner via VESTAL POINT CAPITAL, LLC | MANAGER since Apr 2023 | 25–50% | Individual |
| J.P. MORGAN TRUST COMPANY OF DELAWARE Indirect owner via MAPLEWOOD 1 TRUST | ADMINISTRATIVE TRUSTEE since Dec 2025 | 25–50% | Domestic Entity |
| MAPLEWOOD 1 TRUST Indirect owner via MAPLEWOOD 1 HOLDINGS LLC | SOLE OWNER since Dec 2025 | 25–50% | Domestic Entity |
| WILDER, BLYTHE, ADLER Indirect owner via MAPLEWOOD 1 HOLDINGS LLC | MANAGER since Dec 2025 | 25–50% | Individual |
Ownership & leadership changes · 2 filings with changes since Mar 17, 2023
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedJ.P. MORGAN TRUST COMPANY OF DELAWARE · ADMINISTRATIVE TRUSTEE · 25–50% · indirect via MAPLEWOOD 1 TRUST
- AddedMAPLEWOOD 1 HOLDINGS LLC · LIMITED PARTNER · 25–50%
- AddedMAPLEWOOD 1 TRUST · SOLE OWNER · 25–50% · indirect via MAPLEWOOD 1 HOLDINGS LLC
- AddedVESTAL POINT CAPITAL, LLC · GENERAL PARTNER · Less than 5% · control person
- AddedWILDER, BLYTHE, ADLER · MANAGER · 25–50% · indirect via MAPLEWOOD 1 HOLDINGS LLC
- AddedWILDER, RYAN, CHRISTOPHER · MANAGER · 25–50% · indirect via VESTAL POINT CAPITAL, LLC · control person
- ChangedWILDER, RYAN, CHRISTOPHER · ownership 75% or more → 25–50%
- AddedCARROLL, BENJAMIN, GERMAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedMENKOV, ILKO, LATCHEZAROV · PARTNER, COO AND CCO · 5–10% · control person
- ListedWILDER, RYAN, CHRISTOPHER · MANAGING PARTNER AND CHIEF INVESTMENT OFFICER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- United Therapeutics Corp$191.2M +430.0%
- Neurocrine Biosciences Inc$152.2M +92.4%
- Abivax SA$146.1M +87.4%
- BioMarin Pharmaceutical Inc$142.8M +70.7%
- Zimmer Biomet Holdings Inc$103.3M +601.6%
Top Trims
- Revolution Medicines Inc-$146.7M -63.5%
- Repligen Corp-$54.4M -49.9%
- Alcon AG-$26.7M -44.3%
- Immunocore Holdings PLC-$26.3M -31.5%
- Alto Neuroscience Inc-$25.7M -55.4%
New Positions
- Abbott Laboratories$127.0M
- Ascendis Pharma A/S$100.0M
- Insmed Inc$26.7M
- First Tracks Biotherapeutics I$20.4M
- Avalo Therapeutics Inc$14.3M
Exited Positions
- Apogee Therapeutics Inc$92.6M
- Ascendis Pharma A/S$85.8M
- Scholar Rock Holding Corp$65.1M
- Vera Therapeutics Inc$55.0M
- Terns Pharmaceuticals Inc$52.7M
Vestal Point Capital, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BioMarin Pharmaceutical Inc | BMRN | 09061G101 | $344.8M | 8.06% | 6,025,000 | SH |
| 2 | Neurocrine Biosciences Inc | NBIX | 64125C109 | $316.8M | 7.40% | 1,880,000 | SH |
| 3 | Abivax SA | ABVX | 00370M103 | $313.1M | 7.32% | 2,349,443 | SH |
| 4 | United Therapeutics Corp | UTHR | 91307C102 | $235.7M | 5.51% | 435,000 | SH |
| 5 | Enliven Therapeutics Inc | ELVN | 29337E102 | $203.0M | 4.74% | 4,000,000 | SH |
| 6 | Nurix Therapeutics Inc | NRIX | 67080M103 | $195.3M | 4.56% | 8,050,000 | SH |
| 7 | Bicara Therapeutics Inc | BCAX | 055477103 | $155.9M | 3.64% | 5,250,000 | SH |
| 8 | Taysha Gene Therapies Inc | TSHA | 877619106 | $132.2M | 3.09% | 19,415,000 | SH |
| 9 | Arrowhead Pharmaceuticals Inc | ARWR | 04280A100 | $128.4M | 3.00% | 1,575,000 | SH |
| 10 | Abbott Laboratories | ABT | 002824100 | $127.0M | 2.97% | 1,400,000 | SH |
| 11 | Zimmer Biomet Holdings Inc | ZBH | 98956P102 | $120.5M | 2.82% | 1,400,000 | SH |
| 12 | Disc Medicine Inc | IRON | 254604101 | $113.4M | 2.65% | 1,550,000 | SH |
| 13 | Monte Rosa Therapeutics Inc | GLUE | 61225M102 | $111.3M | 2.60% | 4,600,000 | SH |
| 14 | Insulet Corp | PODD | 45784P101 | $102.0M | 2.38% | 670,000 | SH |
| 15 | Ascendis Pharma A/S | ASND | K08588103 | $100.0M | 2.34% | 375,000 | SH |
| 16 | AstraZeneca PLC | AZN | G0593M107 | $85.3M | 1.99% | 450,000 | SH |
| 17 | Sanofi SA | SNY | 80105N105 | $85.3M | 1.99% | 2,000,000 | SH |
| 18 | Revolution Medicines Inc | RVMD | 76155X100 | $84.3M | 1.97% | 450,000 | SH |
| 19 | BioCryst Pharmaceuticals Inc | BCRX | 09058V103 | $83.0M | 1.94% | 8,300,000 | SH |
| 20 | Dyne Therapeutics Inc | DYN | 26818M108 | $75.0M | 1.75% | 3,375,000 | SH |
| 21 | Nektar Therapeutics | NKTR | 640268306 | $69.8M | 1.63% | 1,000,000 | SH |
| 22 | Globus Medical Inc | GMED | 379577208 | $67.2M | 1.57% | 850,000 | SH |
| 23 | Tarsus Pharmaceuticals Inc | TARS | 87650L103 | $66.1M | 1.54% | 1,050,000 | SH |
| 24 | Immatics NV | IMTX | N44445109 | $62.6M | 1.46% | 6,175,000 | SH |
| 25 | Trevi Therapeutics Inc | TRVI | 89532M101 | $57.8M | 1.35% | 3,100,000 | SH |
| 26 | Immunocore Holdings PLC | IMCR | 45258D105 | $57.1M | 1.34% | 1,800,000 | SH |
| 27 | Repligen Corp | RGEN | 759916109 | $54.6M | 1.28% | 400,000 | SH |
| 28 | Bristol-Myers Squibb Co | BMY | 110122108 | $46.1M | 1.08% | 800,000 | SH |
| 29 | uniQure NV | QURE | N90064101 | $43.1M | 1.01% | 935,000 | SH |
| 30 | Xenon Pharmaceuticals Inc | XENE | 98420N105 | $42.3M | 0.99% | 700,000 | SH |
| 31 | Bright Minds Biosciences Inc | DRUG | 10919W405 | $38.3M | 0.89% | 545,000 | SH |
| 32 | Madrigal Pharmaceuticals Inc | MDGL | 558868105 | $34.9M | 0.82% | 65,000 | SH |
| 33 | Alcon AG | ALC | H01301128 | $33.5M | 0.78% | 500,000 | SH |
| 34 | Myriad Genetics Inc | MYGN | 62855J104 | $32.7M | 0.77% | 5,735,000 | SH |
| 35 | Rapport Therapeutics Inc | RAPP | 75383L102 | $30.4M | 0.71% | 730,000 | SH |
| 36 | Crescent Biopharma Inc | CBIO | G2545C104 | $29.3M | 0.69% | 1,630,000 | SH |
| 37 | GE HealthCare Technologies Inc | GEHC | 36266G107 | $28.8M | 0.67% | 450,000 | SH |
| 38 | Insmed Inc | INSM | 457669307 | $26.7M | 0.62% | 250,000 | SH |
| 39 | Viking Therapeutics Inc | VKTX | 92686J106 | $26.5M | 0.62% | 680,000 | SH |
| 40 | Beta Bionics Inc | BBNX | 08659B102 | $25.1M | 0.59% | 1,600,000 | SH |
| 41 | Regeneron Pharmaceuticals Inc | REGN | 75886F107 | $24.9M | 0.58% | 40,000 | SH |
| 42 | Solid Biosciences Inc | SLDB | 83422E204 | $21.6M | 0.50% | 2,160,000 | SH |
| 43 | Alto Neuroscience Inc | ANRO | 02157Q109 | $20.7M | 0.48% | 785,000 | SH |
| 44 | First Tracks Biotherapeutics I | TRAX | 337185102 | $20.4M | 0.48% | 1,013,000 | SH |
| 45 | Lexeo Therapeutics Inc | LXEO | 52886X107 | $20.1M | 0.47% | 4,320,000 | SH |
| 46 | Savara Inc | SVRA | 805111101 | $16.8M | 0.39% | 2,720,000 | SH |
| 47 | Damora Therapeutics Inc | DMRA | 36322Q206 | $15.0M | 0.35% | 575,000 | SH |
| 48 | SpyGlass Pharma Inc | SGP | 85220G109 | $14.9M | 0.35% | 670,000 | SH |
| 49 | Tectonic Therapeutic Inc | TECX | 878972108 | $14.6M | 0.34% | 425,000 | SH |
| 50 | Avalo Therapeutics Inc | AVTX | 05338F306 | $14.3M | 0.33% | 775,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $4.28B | 68 | 0001974915-26-000005 |
| 2026-03-31 | 2026-05-15 | $3.58B | 90 | 0001974915-26-000004 |
| 2025-12-31 | 2026-02-17 | $2.94B | 76 | 0001974915-26-000002 |
| 2025-09-30 | 2025-11-14 | $2.21B | 81 | 0001974915-25-000008 |
SUITE 602
NEW YORK, NY 10012